PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.\', \'Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.\', \'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK; Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.\', \'Berry Consultants, Austin, TX, USA; Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN, USA.\', \'College of Medicine and Health, University of Exeter, Exeter, UK; National Institute for Health Research Clinical Research Network, National Institute for Health Research, London, UK.\', \'National Institute for Health Research Clinical Research Network, National Institute for Health Research, London, UK; Royal College of General Practitioners, London, UK.\', \'Oxford Clinical Trials Research Unit, Botnar Research Centre, University of Oxford, Oxford, UK.\', \'Berry Consultants, Austin, TX, USA.\', \'National Heart and Lung Institute, Imperial College, London, UK.\', \'Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK; UQ Centre for Clinical Research, University of Queensland, Brisbane, QLD, Australia.\', \'National Institute for Health Research Oxford Biomedical Research Centre, Oxford, UK.\', \'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK. Electronic address: richard.hobbs@phc.ox.ac.uk.\', \'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK. Electronic address: christopher.butler@phc.ox.ac.uk.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S0140-6736(21)01744-X10.1016/S0140-6736(21)01744-X
?:hasPublicationType
?:journal
  • Lancet (London, England)
is ?:pmid of
?:pmid
?:pmid
  • 34388395
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all